Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (121-130 of 275) with videos related to

Pageof 28
Sort By:
Lung Cancer (Amsterdam, Netherlands)|July 30, 2024
Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLCFilippo Tommaso Gallina, Vittoria Balzano, Nicla Porciello, et al.
Journal of Clinical Pathology|August 17, 2021
Not enough can be enough: feasibility of the Idylla <i>EGFR</i> mutation test when reuse of stained tissue slides is the only option availableCristiana Ercolani, Anna Di Benedetto, Claudia Bonomo, et al.
Translational Lung Cancer Research|September 27, 2019
The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patientsHuijuan Li, Yangyang Xu, Bing Wan, et al.
Clinical Lung Cancer|April 16, 2024
Neutrophil-to-Lymphocyte Ratio and Risk of Nodal Metastasis in Early-Stage Lung Adenocarcinoma: A Brief Report From a Multicentric AnalysisFilippo Tommaso Gallina, Marco Chiappetta, Riccardo Tajè, et al.
Lung Cancer (Amsterdam, Netherlands)|December 4, 2003
Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancerFederico Cappuzzo, Filippo De Marinis, Fabrizio Nelli, et al.
Clinical Lung Cancer|February 4, 2014
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Filippo de Marinis, Federico Cappuzzo, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2025
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trialsAndrea Torchia, Arianna Sabatini, Elisabetta Bengala, et al.
Clinical Colorectal Cancer|February 8, 2014
MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodiesFederico Cappuzzo, Andrea Sacconi, Lorenza Landi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLCFederico Cappuzzo, Vanesa Gregorc, Elisa Rossi, et al.
Frontiers in Oncology|November 29, 2023
Analysis of predictive factors of unforeseen nodal metastases in resected clinical stage I NSCLCFilippo Tommaso Gallina, Daniele Marinelli, Riccardo Tajè, et al.
Pageof 28

Showing results (121-130 of 275) with videos related to

Sort By:
Pageof 28
Lung Cancer (Amsterdam, Netherlands)|July 30, 2024
Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLCFilippo Tommaso Gallina, Vittoria Balzano, Nicla Porciello, et al.
Journal of Clinical Pathology|August 17, 2021
Not enough can be enough: feasibility of the Idylla <i>EGFR</i> mutation test when reuse of stained tissue slides is the only option availableCristiana Ercolani, Anna Di Benedetto, Claudia Bonomo, et al.
Translational Lung Cancer Research|September 27, 2019
The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patientsHuijuan Li, Yangyang Xu, Bing Wan, et al.
Clinical Lung Cancer|April 16, 2024
Neutrophil-to-Lymphocyte Ratio and Risk of Nodal Metastasis in Early-Stage Lung Adenocarcinoma: A Brief Report From a Multicentric AnalysisFilippo Tommaso Gallina, Marco Chiappetta, Riccardo Tajè, et al.
Lung Cancer (Amsterdam, Netherlands)|December 4, 2003
Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancerFederico Cappuzzo, Filippo De Marinis, Fabrizio Nelli, et al.
Clinical Lung Cancer|February 4, 2014
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Filippo de Marinis, Federico Cappuzzo, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2025
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trialsAndrea Torchia, Arianna Sabatini, Elisabetta Bengala, et al.
Clinical Colorectal Cancer|February 8, 2014
MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodiesFederico Cappuzzo, Andrea Sacconi, Lorenza Landi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLCFederico Cappuzzo, Vanesa Gregorc, Elisa Rossi, et al.
Frontiers in Oncology|November 29, 2023
Analysis of predictive factors of unforeseen nodal metastases in resected clinical stage I NSCLCFilippo Tommaso Gallina, Daniele Marinelli, Riccardo Tajè, et al.
Pageof 28